knowledge -WSS

knowledge

author：focus 2025-09-05 15:35:34 - browse：1

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Study: Hearing aids may slow cognitive decline in those at risk

explore

WSS

Biden administration sends mixed signals on US soldier who crossed into North Korea

More hospitals are billing patients as online messages surge

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

A strong 6.5

Medtronic CEO on promising devices for diabetes, hypertension

Traditional Chinese medicine benefits explored in new JAMA study

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical records are filled with copy

Cassava reveals details — and problems — with Alzheimer's study

Jerome Adams on the need for new antivirals for Covid

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

23andMe had bad news about my health. I wish a person had delivered it

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

New air purifier tech could be key to improving indoor air quality

Why Sanofi got shellacked over its spinoff

State Dept. review finds Biden bears some blame for Afghanistan failures

Testing for cancer recurrence creates a new limbo for patients

entertainment

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

CDC recommends rationing of RSV shot due to shortages

15 die by electrocution after transformer explodes in northern India

Twill hunts for pharma partner to market its depression app

Traditional Chinese medicine benefits explored in new JAMA study

hotspot

leisure time

explore

hotspot